<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04282278</url>
  </required_header>
  <id_info>
    <org_study_id>HRHB-C001</org_study_id>
    <nct_id>NCT04282278</nct_id>
  </id_info>
  <brief_title>Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor</brief_title>
  <official_title>Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University Fourth Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess time window, efficacy and safety of patients who
      receive anti-PD-1 antibody multimodal combination as first-line treatment of advanced solid
      tumor.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>evaluated in 24 months since the treatment began</time_frame>
    <description>Baseline to measured date of progression or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>tumor assessment every 6 weeks since the treatment began，up to 24 months</time_frame>
    <description>Baseline to measured stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>tumor assessment every 6 weeks since the treatment began，up to 24 months</time_frame>
    <description>Baseline to measured progressive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>the first day of treatment to death or last survival confirm date,up to 24 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. The number of Participants with adverse events will be recorded at each treatment visit.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab/sintilimab+ Standard chemotherapy</intervention_name>
    <description>Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy）</intervention_name>
    <description>Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Apatinib：250mg，d1，qd，po</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy</intervention_name>
    <description>Camrelizumab/sintilimab：200mg，iv，30min，d7，q3w，24 months Apatinib：250mg，d1，qd，po Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age:18 to 70 years old;

          2. Patients with advanced solid tumors confirmed by histopathology or cytology and
             genetic testing was negative;

          3. None previous chemotherapy, Antiangiogenic targeted therapy, Immune checkpoint
             inhibitors therapy（NOTE: neoadjuvant and adjuvant therapy is allowed）;

          4. At least one measurable lesion (measuring≥10mm on spiral CT scan, satisfying the
             criteria in RECIST1.1);

          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;

          6. Life expectancy greater than or equal to 18 weeks;

          7. Major organ function has to meet the following certeria:

        1) For results of blood routine test HB≥90g/L; ANC≥1.5×109/L; PLT≥90×109/L; 2) For results
        of blood biochemical test ALB≥30g/L ALT and AST&lt;2.5×ULN, but&lt;5×ULN if the transferanse
        elevation is due to liver metastases； TBIL≤1.5×ULN； Serum creatinine ≤1.5×ULN; 8. Left
        ventricular ejection fraction (LVEF) ≥50%; 9. Women of childbearing age must have
        contraceptive measures or have test pregnancy (serum or urine) enroll the study before 14
        days, and the results must be negative, and take the methods of contraception during the
        test and the last to have drugs after 8 weeks. Men must be contraception or has
        sterilization surgery during the test and the last to have drugs after 8 weeks; 10.
        Participants were willing to join in this study, and written informed consent, good
        adherence, cooperate with the follow-up.

        Exclusion Criteria:

          1. Patients with symptomatic brain metastases;

          2. Subjects with immunosuppressive medications within 14 days of first administration of
             study treatment, prednisone is used for less than 1 week, excluding nasal spray and
             inhaled corticosteroids or physiological doses of systemic steroid hormones (no more
             than 10 mg / day of prednisolone or other corticosteroids of equivalent pharmaceutical
             physiological dose);

          3. The patient has any active autoimmune disease or a history of autoimmune disease (such
             as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia,
             uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis,
             Hyperthyroidism; patients with vitiligo; Asthma has been completely relieved in
             childhood, and patients who do not need any intervention after adulthood can be
             included; asthma patients who require bronchodilators for medical intervention cannot
             be included);

          4. Patients with other malignant tumors within 5 years (except for the treated skin basal
             cell carcinoma and cervical carcinoma in situ, dual or multiple primary tumors);

          5. Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome
             (AIDS), active hepatitis B (HBV-DNA ≥1000 IU/ml) or hepatitis C (positive hepatitis C
             antibody, and HCV-RNA is higher than the lower limit of detection of the analytical
             method) or co-infection with hepatitis B and C, requiring antiviral treatment during
             the study ;

          6. 3 months before study drug administration, the following occurred: myocardial
             infarction, severe / unstable angina pectoris, grade III-IV cardiac insufficiency
             according to New York Heart Association(NYHA) criteria, uncontrolled arrhythmias
             (including QTcF interval male&gt; 450 ms, female&gt; 470 ms ,The QTcF interval is calculated
             using Fridericia formula), symptomatic congestive heart failure, cerebrovascular
             accidents (including transient ischemic attack or symptomatic pulmonary embolism), in
             stable phase, need a cardiovascular physician evaluation;

          7. Severe infections within 2 weeks before study drug administration (eg. Need
             intravenous drip antibiotics, antifungals or antivirals) or &gt;38.5℃during screening
             visits or on the first scheduled day of dosing;

          8. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell
             transplantation;

          9. Less than 4 weeks from the last clinical trial;

         10. History of psychiatric drugs abuse and can't quit or patients with mental disorders;

         11. The researchers think inappropriate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baoen Shan, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Medical University Fourth Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jian Shi, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Medical University Fourth Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Shi, Ph.D</last_name>
    <phone>13831110729</phone>
    <email>shijian6668@126.com</email>
  </overall_contact>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University Fourth Hospital</investigator_affiliation>
    <investigator_full_name>Jian SHI</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

